Launching a two-pronged attack on cancer’s ability to safeguard its DNA could offer an effective new way of treating the disease, a new study reports. Scientists have found that small molecules that ...

This led to the development of the company’s lead asset, ATX-01, a first-in-class therapy that targets miR-23b, now in phase 1/2 testing in the US, Canada, UK, and Europe. While studying the ...

Each oval denotes a computation process performing the function indicated by its label, with the labels on arcs between ovals describing the nature of the objects produced and/or consumed by a ...

All of these things can happen in tandem with the City of Yes; they do not conflict, and we should not let anyone claim they are at odds. However, all of the new HPD money and affordability ...

They will be followed up for two years, looking at safety, tolerability, the survival of the cells and the impact on Parkinson's symptoms, with final results due in November 2023. AskBio's ...